Lexeo Therapeutics Management
Management criteria checks 1/4
Lexeo Therapeutics' CEO is R. Townsend, appointed in Jan 2020, has a tenure of 4.33 years. total yearly compensation is $1.74M, comprised of 29.2% salary and 70.8% bonuses, including company stock and options. directly owns 0.39% of the company’s shares, worth $1.77M. The average tenure of the management team and the board of directors is 1.8 years and 1.9 years respectively.
Key information
R. Townsend
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 29.2% |
| CEO tenure | 4.3yrs |
| CEO ownership | 0.4% |
| Management average tenure | 1.8yrs |
| Board average tenure | 1.9yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$69m |
| Dec 31 2023 | US$2m | US$508k | -US$66m |
| Sep 30 2023 | n/a | n/a | -US$67m |
| Jun 30 2023 | n/a | n/a | -US$64m |
| Mar 31 2023 | n/a | n/a | -US$64m |
| Dec 31 2022 | US$705k | US$465k | -US$59m |
| Dec 31 2021 | US$3m | US$411k | -US$51m |
Compensation vs Market: R.'s total compensation ($USD1.74M) is about average for companies of similar size in the US market ($USD2.45M).
Compensation vs Earnings: R.'s compensation has increased whilst the company is unprofitable.
CEO
R. Townsend (42 yo)
4.3yrs
Tenure
US$1,737,218
Compensation
Mr. R. Nolan Townsend is Director of Arbor Biotechnologies, Inc. from November 2023. He is Chief Executive Officer & Director of Lexeo Therapeutics, Inc since January 2020 Before joining Lexeo, Mr. Townsen...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.3yrs | US$1.74m | 0.39% $ 1.8m | |
| Chief Medical Officer & Head of Research | less than a year | US$3.04m | 0% $ 0 | |
| Chief Business & Legal Officer | 2.2yrs | US$1.30m | 0% $ 0 | |
| Co-Founder | no data | no data | 4.06% $ 18.7m | |
| Chief Technical Officer | 2.4yrs | US$471.73k | 0.053% $ 242.4k | |
| Senior Vice President of Clinical Development & Translational Science | 1.3yrs | no data | no data | |
| Head of CNS Clinical Development | 1.3yrs | no data | no data | |
| Chief Development Officer | 1.3yrs | no data | 0.050% $ 232.2k | |
| VP & Corporate Controller | 2.3yrs | no data | no data |
1.8yrs
Average Tenure
48.5yo
Average Age
Experienced Management: LXEO's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.3yrs | US$1.74m | 0.39% $ 1.8m | |
| Co-Founder | 1.5yrs | no data | 4.06% $ 18.7m | |
| Independent Director | 3.5yrs | US$6.41k | no data | |
| Independent Director | 2.3yrs | US$7.38k | no data | |
| Independent Director | 3.5yrs | US$10.50k | no data | |
| Independent Director | 2.5yrs | US$406.61k | 0.047% $ 218.3k | |
| Independent Chairman of the Board | 3.3yrs | US$200.15k | 0% $ 0 | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data |
1.9yrs
Average Tenure
66yo
Average Age
Experienced Board: LXEO's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.